Detailansicht

Wissensnetz

Person

Peter Borchmann

Internist

Name	Peter Borchmann
Ort	Köln (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Internist (charakteristischer Beruf) Arzt
Beziehung	Universitätsklinikum Köln (Oberarzt Klinik I)
Quelle	Homepage: https://innere1.uk-koeln.de/klinik/direktor-teams/oberaerzte/ (Stand: 14.04.2020)
Datensatztyp	Person
GND-Nummer	107278842X
Datensatz-ID	107278842X
Beteiligt an alle anzeigen Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma Moderne Radiotherapie beim Hodgkin-Lymphom : Überlegungen zu einer personalisierten Planung Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era Radiotherapy in the GHSG HD 16 and HD 17 trials – quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial FDG-Positronenemissionstomographie-Computertomographie und neue Chancen zur Therapiesteuerung Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial Polychemotherapie im ersten Rezidiv eines klassischen Hodgkin Lymphoms nach initial frühem Stadium Transfusionsbedarf bei Patienten mit Niedrigrisiko Myelodysplastischem Syndrom in der Regelversorgung in Deutschland Validierung einer digitalen Applikation zur Qualitätssicherung von Tumorboards Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG) Positronenemissionstomographie beim Hodgkin-Lymphom CD30-positive Lymphone Das Hodgkin-Lymphom Das Hodgkin-Lymphom Untersuchungen zur Expression des Proliferationsmarkers MIB1 (Ki-67) und des Tumorsuppressorgens p53 am urothelialen Karzinom der Harnblase

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Peter Borchmann

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Moderne Radiotherapie beim Hodgkin-Lymphom : Überlegungen zu einer personalisierten Planung

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era

Radiotherapy in the GHSG HD 16 and HD 17 trials – quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

FDG-Positronenemissionstomographie-Computertomographie und neue Chancen zur Therapiesteuerung

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma

9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

Polychemotherapie im ersten Rezidiv eines klassischen Hodgkin Lymphoms nach initial frühem Stadium

Transfusionsbedarf bei Patienten mit Niedrigrisiko Myelodysplastischem Syndrom in der Regelversorgung in Deutschland

Validierung einer digitalen Applikation zur Qualitätssicherung von Tumorboards

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)

Positronenemissionstomographie beim Hodgkin-Lymphom

CD30-positive Lymphone

Das Hodgkin-Lymphom

Das Hodgkin-Lymphom

Untersuchungen zur Expression des Proliferationsmarkers MIB1 (Ki-67) und des Tumorsuppressorgens p53 am urothelialen Karzinom der Harnblase